Piperazinedione in patients with advanced malignant melanoma: a Southwest Oncology Group study.

Abstract

Piperazinedione was administered in doses of 9 or 12 mg/m2 by iv infusion every 3 weeks in 28 patients with previously treated malignant melanoma. Of the 25 evaluable patients, 72% had drug-induced toxicity: 40% had leukopenia, 56% had thrombocytopenia, 40% had anemia, and 16% had nausea and vomiting. None of these patients had partial remission, two had stable disease, and the remaining 23 had definite progression of their disease in spite of adequate trial with this agent.

• Authors: M Al-Sarraf, T Thigpen, C W Groppe, A Haut, F Padilla
• Journal: Cancer treatment reports (Cancer Treat Rep) Vol. 62 Issue 7 Pg. 1101-3 (Jul 1978) ISSN: 0361-5960 [Print] United States
• PMID: 356973 (Publication Type: Clinical Trial, Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Antibiotics, Antineoplastic
• Piperazines

Topics

• Adult
• Aged
• Antibiotics, Antineoplastic (administration & dosage, adverse effects, therapeutic use)
• Bone Marrow (drug effects)
• Clinical Trials as Topic
• Drug Evaluation
• Female
• Humans
• Male
• Melanoma (drug therapy)
• Middle Aged
• Neoplasm Metastasis
• Piperazines (administration & dosage, adverse effects, therapeutic use)